Innovative Treatments for Demodex Blepharitis and MGD: Real-World Outcomes and Implementation - On Demand Video

Activity Description
 
In this video Jacob Lang, OD and Cecelia Koetting, OD explores innovative treatments for Demodex blepharitis and MGD, highlighting real-world outcomes and emphasizing early intervention, personalized care, and patient adherence to improve eyelid margin health and maintain long-term therapeutic success.

Accreditation

Sponsored by
NSUOCO



NSUOCO

The Fundingsland Group, LLC is a COPE-Approved Administrator.

COPELogo w AccreditationThis activity, COPE Activity Number 129972, is accredited by COPE for continuing education for optometrists. This course is approved for .25 hours of CE.

Course # 95700-TD
Activity #: 129972

COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.

Release Date: 01-27-2025
Expiration Date: 01-27-2026

Grant Support Statement

This activity is supported by unrestricted educational grants from Johnson & Johnson Vision, Sight Sciences, and Tarsus Pharmaceuticals, Inc. 

Faculty

J. Lang Bio Pic

     

Jacob Lang, OD, FAAO


Cecelia Koetting Headshot 2024

   

Cecelia Koetting, OD, FAAO

Progress